| Autor: |
Chalfin, Heather, Pramparo, Tiziano, Mortazavi, Amir, Niglio, Scot A., Schonhoft, Joseph, Jendrisak, Adam, Chu, Yen-Lin, Richardson, Robin, Krupa, Rachel, Anderson, Amanda, Wang, Yipeng, Dittamore, Ryan, Pal, Sumanta K., Lara, Primo N., Stein, Mark N., Quinn, David, Steinberg, Seth M., Cordes, Lisa M., Ley, Lisa, Mallek, Marissa, Ortiz, Olena Sierra, Costello, Rene, Cadena, Jacqueline, Diaz, Carlos, Gulley, James L., Dahut, William L., Streicher, Howard, Wright, John J., Trepel, Jane B., Bottaro, Donald P., Apolo, Andrea B. |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Clin Cancer Res |
| Popis: |
PURPOSE: Circulating tumor cells (CTCs) are under investigation as a minimally invasive liquid biopsy that may improve risk stratification and treatment selection. CTCs uniquely allow for digital pathology of individual malignant cell morphology and marker expression. We compared CTC features and T-cell counts with survival endpoints in a cohort of metastatic genitourinary (mGU) cancer patients treated with combination immunotherapy. EXPERIMENTAL DESIGN: Markers evaluated included pan-CK/CD45/PD-L1/DAPI for CTCs and CD4/CD8/Ki-67/DAPI for T cells. ANOVA was used to compare CTC burden and T-cell populations across time points. Differences in survival and disease progression were evaluated using the maximum log-rank test. RESULTS: From 12/2016–01/2019, 183 samples from 81 patients were tested. CTCs were found in 75% of patients at baseline. CTC burden was associated with shorter OS at baseline (p=0.022) but not on therapy. Five morphologic subtypes were detected, and the presence of 2 specific subtypes with unique cellular features at baseline and on therapy were associated with worse OS (0.9–2.3 mos vs. 28.2 mos,p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
